Engineering Next Generation NKCell Therapies to Enhance Persistence in Solid Tumors

• Showcasing novel NK-cell engineering strategies to enhance serial killing activity and improve functional persistence
• Ensuring better tolerability and improved safety profile
• Presenting preclinical efficacy, safety, and pharmacokinetic data demonstrating enhanced anti-tumor activity and translational potential

Speakers:

Raphael OGNAR

President & CEO, Co-founder

NKILT Therapeutics